Evaluation of H-FABP as a marker of ongoing myocardial damage using hGH transgenic mice

Naraoka, Hitoshi; Ito, Kyoko; Suzuki, M; Naito, Kunihiko; Tojo, Hideaki

doi:10.1016/j.cccn.2005.05.027

Cited by 6 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although widely distributed, ALT is mainly used to assess hepatocellular damage, cardiac muscle damage (Naraoka et al 2005;Ray et al 2005), and testicular injury (Santos et al 2005). ALT activity has been used as an indicator of hepatic injury of mice infected with mouse hepatitis virus (Fassati et al 1969).…”

Section: Aspartate Aminotransferase (Ast)mentioning

confidence: 99%

See 1 more Smart Citation

Clinical Chemistry of the Laboratory Mouse

Quimby¹,

Luong²

2007

The Mouse in Biomedical Research

View full text Add to dashboard Cite

Section: Aspartate Aminotransferase (Ast)mentioning

confidence: 99%

“…Mice infected with the LDH virus (LDV) exhibit increased serum concentrations of LDH, isocitric dehydrogenase, malic dehydrogenase, phosphohexase isomerase, and AST (Notkins 1965). Along with AST and CK, LDH is considered an excellent marker for cardiac injury (Naraoka et al 2005;Ray et al 2005).…”

Section: Lactate Dehydrogenase (Ldh)mentioning

confidence: 99%

Clinical Chemistry of the Laboratory Mouse

Quimby¹,

Luong²

2007

The Mouse in Biomedical Research

View full text Add to dashboard Cite

“…Biochemical markers have been used for decades to provide a noninvasive means of diagnosing cardiac injury . Numerous examples exist in the literature describing the use of myocardium-specific proteins as markers of congestive heart failure, myocardial infarction, cardiac necrosis, and other heart-related ailments. − Examples of cardiac markers include the troponins (cTnT, cTnI), cardiac natriuretic peptides (BNP, ANP), creatinine kinase isoenzyme MB (CK-MB), heart fatty acid binding protein (hFabp3), and myosin light chain (Myl3). − By evaluating the utility of proven clinical cardiac markers in veterinary species, a panel of biomarkers can be identified to diagnose cardiac injury in studies ranging from early discovery through clinical evaluation. Dolci and Panteghini outlined the key characteristics of an ideal cardiac biomarker as high sensitivity (early onset, high concentration, slow clearance), specificity (only present in target tissue, not detected in healthy subjects), good analytical characteristics, and good clinical characteristics (ability to influence patient therapy and outcome) .…”

mentioning

confidence: 99%

Strategic Use of Immunoprecipitation and LC/MS/MS for Trace-Level Protein Quantification: Myosin Light Chain 1, a Biomarker of Cardiac Necrosis

et al. 2007

View full text Add to dashboard Cite

Myosin light chain 1 (Myl3) is a 23-kDa isoform of one of the subunits of myosin, a protein involved in muscle contraction. Myl3 is presently being studied as a biomarker of cardiac necrosis to predict drug-induced cardiotoxicity, and in the work presented here, an LC/MS/MS assay was developed and validated to measure Myl3 in rat serum. The key steps in this approach involved immunoaffinity purification of Myl3 from serum followed by on-bead digestion with trypsin to release a surrogate peptide. This tryptic peptide was quantified using a synthetic peptide standard and a corresponding stable isotope-labeled internal standard, and the results were stoichiometrically converted to Myl3 serum concentrations. Myl3 concentrations were corrected for peptide recovery following immunoprecipitation and digestion (85%) and showed excellent agreement with synthetic peptide standards. Both the synthetic peptide and His-Myl3 protein were used to evaluate assay accuracy (% RE) and precision (% CV), which were measured on each of 3 days. The synthetic peptide was evaluated over the range of 0.073-7.16 nM, while Myl3 protein QC samples prepared in rat serum were evaluated over the range of 0.13-6.62 nM. To prepare control matrix, endogenous Myl3 was immunodepleted from pooled rat serum. Peptide interday accuracy and precision did not exceed 7.6 and 11.1%, and Myl3 interday accuracy and precision did not exceed 12.9 and 13.2%, respectively. Data are presented from the application of this assay to establish a time course in which rats demonstrated a marked increase in Myl3 serum concentrations following administration of isoproterenol, a beta-adrenergic receptor agonist known to induce cardiac injury. This assay is an example of a larger effort in our laboratory to use LC/MS/MS in conjunction with immunoaffinity techniques to evaluate candidate biomarkers of target organ toxicity and to expedite the development of biomarker assays for drug development.

show abstract

“…This will be discussed in greater detail below, with each classical myocardial injury biomarker and miRNA biomarker based studies. Furthermore, many cardiac biomarkers are not specific to the heart and elevation is difficult to detect in the early stages of myocardial damage/failure [187]. Furthermore, many cardiac biomarkers are not specific to the heart and elevation is difficult to detect in the early stages of myocardial damage/failure [187].…”

Section: Assessment Of Drug-induced Cardiotoxicity: Clinical Diagnosimentioning

confidence: 99%

Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury

Sandhu

Maddock

2013

Clinical Science

View full text Add to dashboard Cite

Development of reliable biomarkers for early clinical assessment of drug-induced cardiotoxicity could allow the detection of subclinical cardiac injury risk in vulnerable patients before irreversible damage occurs. Currently, it is difficult to predict who will develop drug-induced cardiotoxicity owing to lack of sensitivity and/or specificity of currently used diagnostics. miRNAs are mRNA regulators and they are currently being extensively profiled for use as biomarkers due to their specific tissue and disease expression signature profiles. Identification of cardiotoxicity-specific miRNA biomarkers could provide clinicians with a valuable tool to allow prognosis of patients at risk of cardiovascular injury, alteration of a treatment regime or the introduction of an adjunct therapy in order to increase the long-term survival rate of patients treated with cardiotoxic drugs.

show abstract

Evaluation of H-FABP as a marker of ongoing myocardial damage using hGH transgenic mice

Cited by 6 publications

References 30 publications

Clinical Chemistry of the Laboratory Mouse

Clinical Chemistry of the Laboratory Mouse

Strategic Use of Immunoprecipitation and LC/MS/MS for Trace-Level Protein Quantification: Myosin Light Chain 1, a Biomarker of Cardiac Necrosis

Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury

Contact Info

Product

Resources

About